Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
← catalyst calendarNCT07037459 · readout in 680 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
5,056estimated
Sites
628
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-25 | actual | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Heart Failure With Preserved Ejection Fraction
- Heart Failure With Mildly Reduced Ejection Fraction
- Obesity
Interventions
- Drug: Maridebart cafraglutide — also filed as AMG 133, MariTide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events
measured Up to approximately 35 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed